Comprehensive Cancer Centers has announced the hiring of two board-certified physician assistants, Valerie Chang and Nicholas Tieu
Valerie Chang, MMS, PA-C, OMD, see patients at Comprehensive’s Southwest – Southern Hills treatment center, located at 9280 W. Sunset Road in Las Vegas, where she interprets diagnostic tests, such as X-rays or blood tests, helps diagnose patient illness, provides treatment and educates patients and their families on a variety of issues, such as treatment and self-care. Valerie holds a Bachelor of Arts in anthropology from Portland State University, a Master of Medical Science in physician assistant studies from Midwestern University, and a Master of Science in oriental medicine from Wongu University.
Nicholas Tieu, PA-C, works out of Comprehensive’s Central Valley – Twain treatment center, located at 3730 S. Eastern Ave. in Las Vegas. Prior to joining Comprehensive, Nicholas worked as an ophthalmic technician in San Francisco. During this time, he discovered his passion for patient care and education, which lead to the pursuit of a Master of Physician Assistant Studies degree. Nicholas graduated from San Francisco State University with a Bachelor of Science in biology with a focus in physiology before obtaining a Master of Physician Assistant Studies from Touro University Nevada.
About Comprehensive Cancer Centers
Comprehensive Cancer Centers is an award-winning multi-specialty practice comprising medical oncology, hematology, radiation oncology, breast surgery, pulmonary services, cancer genetic counseling clinical research and other infusion services, with treatment centers and offices throughout Southern Nevada. For more than 40 years, the practice has provided oncology services to patients in and out of state with a specialized physician and nursing staff. Comprehensive, an affiliate of The US Oncology Network, offers state-of-the-art technologies, latest advancements in cancer treatment and groundbreaking clinical research trials. The practice participates in more than 150 Phase I, Phase II and Phase III clinical research studies each year and has played a role in developing more than 100 FDA-approved cancer therapies. For more information, visit the company’s website.
